Carleen Cullinane

Stability of adriamycin-induced DNA adducts and interstrand crosslinks

Anne van Rosmalen, Carleen Cullinane, Suzanne M. Cutts, 1995, Nucleic Acids Res..

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Jason Li, Antoni Ribas, Rodney J Hicks, 2014, Cancer discovery.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Joshy George, Peter Campbell, David D L Bowtell, 2012, Cancer research.

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033

David Binns, Carleen Cullinane, D. Binns, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

Rodney J Hicks, Carleen Cullinane, Ricky W Johnstone, 2011, Molecular Cancer Therapeutics.

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

Dario Strbenac, Carleen Cullinane, Anja Heinemann, 2015, Oncotarget.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Carleen Cullinane, Ricky W Johnstone, S. Lowe, 2012, Cancer cell.

Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.

Ben J. Boyd, Christopher J. H. Porter, Carleen Cullinane, 2012, Molecular pharmaceutics.